home / stock / nonof / nonof news


NONOF News and Press, Novo-Nordisk A/S From 11/17/23

Stock Information

Company Name: Novo-Nordisk A/S
Stock Symbol: NONOF
Market: OTC
Website: novonordisk.com

Menu

NONOF NONOF Quote NONOF Short NONOF News NONOF Articles NONOF Message Board
Get NONOF Alerts

News, Short Squeeze, Breakout and More Instantly...

NONOF - Medtronic: 3 Key Issues To Consider Ahead Of Fiscal Q2 2024 Earnings

2023-11-17 09:20:22 ET Summary Medtronic plc will announce its fiscal year 2024 Q2 earnings Tuesday 21st November. Analysts expect Q2 revenues of ~$7.9bn, normalized EPS of $1.18, and GAAP EPS of $0.81. Key areas of focus include the impact of U.S.-China relations, supply chai...

NONOF - Auxier Asset Management Fall 2023 Market Commentary

2023-11-16 06:35:00 ET Summary Jeff Auxier founded Auxier Asset Management and the Auxier Focus Fund in 1999. Jeff's philosophy is based on the conviction that compounding is the most influential element of an investment program. Longer-term bond rates are rising as the bond marke...

NONOF - MedTech stocks gain after Novo Nordisk data for weight loss therapy

2023-11-13 12:13:48 ET More on DexCom, Novo, etc. Novo Nordisk A/S (NVO) Novo Nordisk R&D Investor Event (Transcript) Eli Lilly: Favorable Developments Continue Regarding Anti-Obesity Drug Franchise Eli Lilly and Company (LLY) Presents at UBS Biopharma 2023 Confe...

NONOF - Novo Nordisk A/S (NVO) Novo Nordisk R&D Investor Event (Transcript)

2023-11-13 09:55:26 ET Novo Nordisk A/S (NVO) Novo Nordisk R&D Investor Event November 11, 2023 06:00 PM ET Company Participants Daniel Bohsen - Head of Investor Relations Martin Holst Lange - Executive Vice President, Development Robin Evers - Senior Vice Pr...

NONOF - Eli Lilly expected to add $4.1B U.S. sales from new weight loss drug

2023-11-12 12:00:36 ET More on Eli Lilly Eli Lilly and Company (LLY) Presents at UBS Biopharma 2023 Conference (Transcript) Eli Lilly: Zepbound FDA Approval Is A Sell-The-News Opportunity Eli Lilly's Big Win In The Obesity Space Just Got Bigger Eli Lilly diab...

NONOF - Novo Nordisk details heart benefits of weight loss drug from Phase 3 trial

2023-11-11 10:25:00 ET More on Novo Nordisk Novo Nordisk: Price Could Still Be Justified Novo Nordisk A/S (NVO) Q3 2023 Earnings Call Transcript Novo Nordisk Milks The Obesity Cash Cow - How Long Will It Last? Novo Nordisk pledges $6B to expand API production...

NONOF - Eli Lilly diabetes therapy endorsed in EU for weight loss

2023-11-10 11:34:39 ET More on Eli Lilly Eli Lilly: Zepbound FDA Approval Is A Sell-The-News Opportunity Eli Lilly's Big Win In The Obesity Space Just Got Bigger Eli Lilly: Zepbound For Weight Loss FDA Approved - Time To Believe The Hype? Eli Lilly declines a...

NONOF - Polen Global Growth Q3 2023 Commentary

2023-11-10 09:35:00 ET Summary Polen Capital is a global independently-owned growth equity boutique, led by an experienced team of investment professionals who are committed to preserving and growing the assets of our clients through a prudent and disciplined long-term investment appr...

NONOF - Polen Focus Growth Q3 2023 Commentary

2023-11-09 23:25:00 ET Summary Polen Capital is a global independently-owned growth equity boutique, led by an experienced team of investment professionals who are committed to preserving and growing the assets of our clients through a prudent and disciplined long-term investment appr...

NONOF - UnitedHealth to prefer eight insulin products to cut out-of-pocket costs

2023-11-09 14:02:39 ET More on UnitedHealth UnitedHealth Group: Excellent Healthcare Stock To Buy UnitedHealth Group: Be Prepared For The Next Buying Opportunity UnitedHealth Group: Market Leaders Never Come Cheap UnitedHealth PBM raises reimbursement tier fo...

Previous 10 Next 10